Press release
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
ASCO presentations on Saturday, June 3 at 4:30pm CDT and Monday, June 5 at 3:00pm CDTModerna to host investor event via webcast on Monday, June 5 at 6pm
About this update from Moderna, Inc.
[{"type":"text","content":"ASCO presentations on Saturday, June 3 at 4:30pm CDT and Monday, June 5 at 3:00pm CDTModerna to host investor event via webcast on Monday, June 5 at 6pm CDTCAMBRIDGE, MA / ACCESSWIRE / May 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, have been accepted for presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6 in Chicago, IL. mRNA-4157 (V940) is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.The two abstract titles are:Abstract #LBA9515: Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumabPoster Discussion Session S406; Saturday, June 3 at 4:30 PM - 6:00 PM CDTPresenter: Matteo S. Carlino, PhD, MBBS, FRACP Abstract #LBA9503: Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trialMelanoma/Skin Cancers Oral Abstract Session; Monday, June 5 at 3:00 - 6:00 PM CDTPresenter: Muhammad Adnan Khattak, PhD, FRACP, MBBSModerna Investor EventModerna will host a live webcast on Monday, June 5 from 6:00 - 7:00pm CDT, which will be available under \"Events and Presentations\" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.About mRNA-4157 (V940)mRNA-4157 (V940) is a novel investigational messenger ribonucleic acid (mRNA)-based individualized neoantigen therapy1 consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient's tumor. Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity.Individualized neoantigen therapies are designed to prime the immune system so that a patient can generate an antitumor response specific to their tumor mut...